221 related articles for article (PubMed ID: 33641864)
21. The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
Kiem D; Wagner S; Magnes T; Egle A; Greil R; Melchardt T
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502471
[TBL] [Abstract][Full Text] [Related]
22. Molecular basis and clonal evolution of myeloproliferative neoplasms.
Cleary C; Kralovics R
Clin Chem Lab Med; 2013 Oct; 51(10):1889-96. PubMed ID: 23729579
[TBL] [Abstract][Full Text] [Related]
23. Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants.
Masselli E; Pozzi G; Gobbi G; Merighi S; Gessi S; Vitale M; Carubbi C
Cells; 2020 Sep; 9(9):. PubMed ID: 32967342
[TBL] [Abstract][Full Text] [Related]
24. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
Sun T; Zhang L
Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
[TBL] [Abstract][Full Text] [Related]
25. Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies.
Nasillo V; Riva G; Paolini A; Forghieri F; Roncati L; Lusenti B; Maccaferri M; Messerotti A; Pioli V; Gilioli A; Bettelli F; Giusti D; Barozzi P; Lagreca I; Maffei R; Marasca R; Potenza L; Comoli P; Manfredini R; Maiorana A; Tagliafico E; Luppi M; Trenti T
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672997
[TBL] [Abstract][Full Text] [Related]
26. Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms.
Allain-Maillet S; Bosseboeuf A; Mennesson N; Bostoën M; Dufeu L; Choi EH; Cleyrat C; Mansier O; Lippert E; Le Bris Y; Gombert JM; Girodon F; Pettazzoni M; Bigot-Corbel E; Hermouet S
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32872203
[TBL] [Abstract][Full Text] [Related]
27. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
Yung Y; Lee E; Chu HT; Yip PK; Gill H
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440869
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneity in myeloproliferative neoplasms: Causes and consequences.
O'Sullivan J; Mead AJ
Adv Biol Regul; 2019 Jan; 71():55-68. PubMed ID: 30528537
[TBL] [Abstract][Full Text] [Related]
29. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
Front Immunol; 2020; 11():604142. PubMed ID: 33329600
[TBL] [Abstract][Full Text] [Related]
30. Always stressed but never exhausted: how stem cells in myeloid neoplasms avoid extinction in inflammatory conditions.
Zhao HG; Deininger M
Blood; 2023 Jun; 141(23):2797-2812. PubMed ID: 36947811
[TBL] [Abstract][Full Text] [Related]
31. Co-existence of mutations in myeloproliferative neoplasms and their clinical significance: a prognostic approach.
Homaei Hadad E; Pezeshki SMS; Shahrabi S; Saki Malehi A; Saki N
Expert Rev Hematol; 2020 Nov; 13(11):1289-1301. PubMed ID: 32886563
[TBL] [Abstract][Full Text] [Related]
32. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
Coltro G; Loscocco GG; Vannucchi AM
Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
[TBL] [Abstract][Full Text] [Related]
33. Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm.
Wang JC; Kundra A; Andrei M; Baptiste S; Chen C; Wong C; Sindhu H
Leuk Res; 2016 Apr; 43():39-43. PubMed ID: 26943702
[TBL] [Abstract][Full Text] [Related]
34. The role of leukocytes in myeloproliferative neoplasm thromboinflammation.
Liu Y; Wang Y; Huang G; Wu S; Liu X; Chen S; Luo P; Liu C; Zuo X
J Leukoc Biol; 2024 May; 115(6):1020-1028. PubMed ID: 38527797
[TBL] [Abstract][Full Text] [Related]
35. TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms.
Kovačić M; Mitrović-Ajtić O; Beleslin-Čokić B; Djikić D; Subotički T; Diklić M; Leković D; Gotić M; Mossuz P; Čokić VP
Cell Oncol (Dordr); 2018 Oct; 41(5):541-553. PubMed ID: 29946821
[TBL] [Abstract][Full Text] [Related]
36. Environmental Factors, Lifestyle Risk Factors, and Host Characteristics Associated With Philadelphia Negative Myeloproliferative Neoplasm: A Systematic Review.
Allahverdi N; Yassin M; Ibrahim M
Cancer Control; 2021; 28():10732748211046802. PubMed ID: 34645293
[TBL] [Abstract][Full Text] [Related]
37. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
[TBL] [Abstract][Full Text] [Related]
38. Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.
Geyer HL; Dueck AC; Scherber RM; Mesa RA
Mediators Inflamm; 2015; 2015():284706. PubMed ID: 26538823
[TBL] [Abstract][Full Text] [Related]
39. Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.
Rosti V; Campanelli R; Massa M; Viarengo G; Villani L; Poletto V; Bonetti E; Catarsi P; Magrini U; Grolla AA; Travelli C; Genazzani AA; Barosi G
Am J Hematol; 2016 Jul; 91(7):709-13. PubMed ID: 27074203
[TBL] [Abstract][Full Text] [Related]
40. Myeloproliferative neoplasms - blurring the lines between cancer and chronic inflammatory disorder.
Soyfer EM; Fleischman AG
Front Oncol; 2023; 13():1208089. PubMed ID: 37361587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
